Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol

[1] Al-Batran SE(2019)Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Lancet 393 1948-1957

[2] Homann N(2012)Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer Clin Nutr 31 74-77

[3] Pauligk C(2003)Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy Cancer 98 1521-1530

[4] Awad S(2000)Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial JPEN J Parenter Enteral Nutr 24 7-14

[5] Tan BH(2017)Weight loss and quality of life in patients surviving 2 years after gastric cancer resection Eur J Surg Oncol 43 1337-1343

[6] Cui H(2016)patterns and predictors of weight loss after gastrectomy for cancer Ann Surg Oncol 23 1639-1645

[7] Becker K(2017)Implication of atypical supraclavicular F18-fluorodeoxyglucose uptake in patients with breast cancer: association between brown adipose tissue and breast cancer Oncol Lett 14 7025-7030

[8] Mueller JD(2021)Results of the observational prospective realFLOT study BMC Cancer 21 1086-318

[9] Schulmacher C(2016)Measuring abdominal circumference and skeletal muscle from a single cross-sectional computed tomography image: a step-by-step guide for clinicians using National Institutes of Health ImageJ JPEN J Parenter Enteral Nutr 40 308-2815

[10] Bozzetti F(2021)Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial J Clin Oncol 39 2803-330

[1] Al-Batran SE(2019)Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Lancet 393 1948-1957

[2] Homann N(2012)Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer Clin Nutr 31 74-77

[3] Pauligk C(2003)Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy Cancer 98 1521-1530

[4] Awad S(2000)Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial JPEN J Parenter Enteral Nutr 24 7-14

[5] Tan BH(2017)Weight loss and quality of life in patients surviving 2 years after gastric cancer resection Eur J Surg Oncol 43 1337-1343

[6] Cui H(2016)patterns and predictors of weight loss after gastrectomy for cancer Ann Surg Oncol 23 1639-1645

[7] Becker K(2017)Implication of atypical supraclavicular F18-fluorodeoxyglucose uptake in patients with breast cancer: association between brown adipose tissue and breast cancer Oncol Lett 14 7025-7030

[8] Mueller JD(2021)Results of the observational prospective realFLOT study BMC Cancer 21 1086-318

[9] Schulmacher C(2016)Measuring abdominal circumference and skeletal muscle from a single cross-sectional computed tomography image: a step-by-step guide for clinicians using National Institutes of Health ImageJ JPEN J Parenter Enteral Nutr 40 308-2815

[10] Bozzetti F(2021)Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial J Clin Oncol 39 2803-330